Ability of Lactobacillus kefiri LKF01 (DSM32079) to colonize the intestinal environment and modify the gut microbiota composition of healthy individuals

Digestive and Liver Disease

Volumn 49, Issue 3, 2017, Pages 261-267

  Toscano, Marco ^a   De Grandi, Roberta ^a   Miniello, Vito Leonardo ^b   Mattina, Roberto ^a   Drago, Lorenzo ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Intestinal microbiota; Probiotics

Indexed keywords

PROBIOTIC AGENT;

ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTEROIDES; BARNESIELLA; BILOPHILA; BUTYRICICOMONAS; CLOSTRIDIUM; CONTROLLED STUDY; FECES; FEMALE; FLAVONIFRACTOR; GASTROINTESTINAL DISEASE; HAEMOPHILUS; HUMAN; INFLAMMATION; INTESTINE FLORA; ITALIAN (CITIZEN); LACTOBACILLUS; LACTOBACILLUS KEFIRI; MALE; NEXT GENERATION SEQUENCING; NORMAL HUMAN; OSCILLIBACTER; POSTPRANDIAL STATE; PREVOTELLA; PRIORITY JOURNAL; SALMONELLA; STREPTOCOCCUS; SUBDOLIGRANOLUM; VEILLONELLA; HIGH THROUGHPUT SEQUENCING; INTESTINE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; FECES; FEMALE; GASTROINTESTINAL MICROBIOME; HEALTHY VOLUNTEERS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTESTINES; LACTOBACILLUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROBIOTICS;

EID: 85007560499     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2016.11.011     Document Type: Article

References (29)

1. [1] Hemarajata, P., Versalovic, J., Effects of probiotics on gut microbiota: mechanisms of intestinal immunomodulation and neuromodulation. Therapeutic Advances in Gastroenterology 6 (2013), 39–51.
2. [2] FAO/WHO. Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Includin; 2001.
3. [3] Ouwehand, A.C., Salminen, S., Isolauri, E., Probiotics: an overview of beneficial effects. Antonie van Leeuwenhoek 82 (2002), 279–289.
4. [4] Mayor, S., Probiotics have no effect on gut microbiota in healthy people, review suggests. BMJ, 353, 2016, i2617.
5. [5] Kristensen, N.B., Bryrup, T., Allin, K.H., et al. Alterations in fecal microbiota composition by probiotic supplementation in healthy adults: a systematic review of randomized controlled trials. Genome Medicine, 8, 2016, 52.
6. [6] Drago, L., Toscano, M., De Vecchi, E., et al. Changing of fecal flora and clinical effect of L. salivarius LS01 in adults with atopic dermatitis. Journal of Clinical Gastroenterology 46 (2012), S56–S63.
7. [7] Niccoli, A.A., Artesi, A.L., Candio, F., et al. Preliminary results on clinical effects of probiotic Lactobacillus salivarius LS01 in children affected by atopic dermatitis. Journal of Clinical Gastroenterology 48 (2014), S34–S36.
8. [8] Drago, L., De Vecchi, E., Gabrieli, A., et al. Immunomodulatory effects of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03, alone and in combination, on peripheral blood mononuclear cells of allergic asthmatics. Allergy Asthma & Immunology Research 7 (2015), 409–413.
9. [9] Pogačić, T., Šinko, S., Zamberlin, Š., et al. Microbiota of kefir grains. Mikrobni Sastav Kefirnih Zrna 63 (2013), 3–14.
10. [10] de Oliveira, L., Machado, A., Miguel, M.A.L., et al. Microbiological, technological and therapeutic properties of kefir: a natural probiotic beverage. Brazilian Journal of Microbiology 44 (2013), 341–349.
11. [11] Drago, L., De Grandi, R., De Vecchi, E., et al. Antibiotic susceptibility profile of a new Lactobacillus kefiri strain. Journal of Global Antimicrobial Resistance 4 (2016), 74–75.
12. [12] Carasi, P., Racedo, S.M., Jacquot, C., et al. Impact of kefir derived Lactobacillus kefiri on the mucosal immune response and gut microbiota. Journal of Immunology Research, 2015, 2015, 361604.
13. [13] Ghoneum, M., Felo, N., Agrawal, S., et al. A novel kefir product (PFT) activates dendritic cells to induce CD4 + T and CD8 + T cell responses in vitro. International Journal of Immunopathology and Pharmacology 28 (2015), 488–496.
14. [14] Castillo, M., Martín-Orúe, S.M., Manzanilla, E.G., et al. Quantification of total bacteria, Enterobacteria and Lactobacilli populations in pig digesta by real-time PCR. Veterinary Microbiology 114 (2006), 165–170.
15. [15] Isolauri, E., Sütas, Y., Kankaanpää, P., et al. Probiotics: effects on immunity. American Journal of Clinical Nutrition 73 (2001), 444S–450S.
16. [16] Butel, M.J., Probiotics, gut microbiota and health. Médecine et Maladies Infectieuses 44 (2014), 1–8.
17. [17] Sanders, M.E., Impact of probiotics on colonizing microbiota of the gut. Journal of Clinical Gastroenterology 45 (2011), S115–S119.
18. [18] Shin, N.R., Whon, T.W., Bae, J.W., Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends in Biotechnology 33 (2015), 496–503.
19. [19] Wexler, H.M., Bacteroides: the good, the bad, and the nitty-gritty. Clinical Microbiology Reviews 20 (2007), 593–621.
20. [20] Ruan, Y., Shen, L., Zou, Y., et al. Comparative genome analysis of Prevotella intermedia strain isolated from infected root canal reveals features related to pathogenicity and adaptation. BMC Genomics, 16, 2015, 122.
21. [21] Guan, S.M., Zhang, M., He, J.J., et al. Mitogen-activated protein kinases and phosphatidylinositol 3-kinase are involved in Prevotella intermedia-induced proinflammatory cytokines expression in human periodontal ligament cells. Biochemical and Biophysical Research Communications 386 (2009), 471–476.
22. [22] Yang, L.C., Tsai, C.H., Huang, F.M., et al. Induction of interleukin-6 gene expression by pro-inflammatory cytokines and black-pigmented Bacteroides in human pulp cell cultures. International Endodontic Journal 36 (2003), 352–357.
23. [23] Larsen, J.M., Steen-Jensen, D.B., Laursen, J.M., et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS One, 7, 2012, e31976.
24. [24] Aragon, G., Graham, D.B., Borum, M., et al. Probiotic therapy for irritable bowel syndrome. Gastroenterologia y Hepatologia 6 (2010), 39–44.
25. [25] Andrew, T.G., Simon, P.O. Jr., Schmitt, C.K., et al. Salmonella typhimurium translocates flagellin across intestinal epithelia, inducing a proinflammatory response. The Journal of Clinical Investigation 107 (2001), 99–109.
26. [26] Katie, S., The host immune response to Clostridium difficile infection. Therapeutic Advances in Infectious Disease 1 (2013), 19–35.
27. [27] van den Bogert, B., Meijerink, M., Zoetendal, E.G., et al. Immunomodulatory properties of Streptococcus and Veillonella isolates from the human small intestine microbiota. PLoS One, 9, 2014, e114277.
28. [28] Lopez-Siles, M., Martinez-Medina, M., Surís-Valls, R., et al. Changes in the abundance of Faecalibacterium prausnitzii phylogroups I and II in the intestinal mucosa of inflammatory bowel disease and patients with colorectal cancer. Inflammatory Bowel Diseases 22 (2016), 28–41.
29. [29] Zhang, M., Qiu, X., Zhang, H., et al. Faecalibacterium prausnitzii inhibits interleukin-17 to ameliorate colorectal colitis in rats. PLoS One, 9, 2014, e109146.